| Patents for A61P 17 - Drugs for dermatological disorders (106,455) |
|---|
| 01/03/2002 | WO2001053344A3 Chondromodulin-i related peptide |
| 01/03/2002 | WO2000061171A9 Uses of mammalian ox2 protein and related reagents |
| 01/03/2002 | US20020002296 Cytoprotective Compounds |
| 01/03/2002 | US20020002197 Tropisetron, Fabesetron, Ramosetron and other drugs useful for treatment of a non-inflammatory local disease of the musculo-sceletal system, of a local irritation condition of a joint or tendom sheath or local manifestation |
| 01/03/2002 | US20020002191 Fluoroalkoxy-substituted benzamide dichloropyridinyl N-oxide PDE4 inhibitor |
| 01/03/2002 | US20020002178 Antiproliferative, -carcinogenic agents, antiinflammatory and -arthritis agents; neurodegenerative diseases, e.g., Alzheimer's disease; cardiovascular disorders; viricides; fungicides |
| 01/03/2002 | US20020002169 Protein kinase inhibitors |
| 01/03/2002 | US20020002165 Growth hormone secretagogues useful for treatment/prevention of osteoporosis |
| 01/03/2002 | US20020002155 Glucocorticoids; antiimflammatory and immunosuppressive agents |
| 01/03/2002 | US20020002138 For use in treatment of diseases associated with reduced levels of growth hormone |
| 01/03/2002 | US20020002131 Providing exogenous antiangiogenic protein to endothelial cells associated with said tissue |
| 01/03/2002 | US20020001630 Angiogenesis inhibitor |
| 01/03/2002 | US20020001624 Medicinal product for the promotion of wound healing |
| 01/03/2002 | US20020001602 Cosmetic/dermatologic cream; stability; nongreasy; composed primarily of water, for treating psoriasis; polyethersiloxane emulsifying agent |
| 01/03/2002 | US20020001600 Method of using lectins for prevention and treatment of skin diseases and disorders |
| 01/03/2002 | DE10028204A1 Verfahren zur Auffindung von medizinisch wertvollen Wirkstoffen Method for identifying medically valuable active ingredients |
| 01/03/2002 | DE10027514A1 Liganden von Integrinrezeptoren Ligands of integrin |
| 01/03/2002 | CA2415873A1 Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists |
| 01/03/2002 | CA2414406A1 Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin |
| 01/03/2002 | CA2414150A1 Modified forms of nonsteroidal anti-inflammatory drugs and uses thereof |
| 01/03/2002 | CA2413683A1 Fused cyclic compounds as modulators of nuclear hormone receptor function |
| 01/03/2002 | CA2413547A1 B7-like molecules and uses thereof |
| 01/03/2002 | CA2413545A1 Methods and compositions for treating pain of the mucous membrane |
| 01/03/2002 | CA2413353A1 Intervertebral disc |
| 01/03/2002 | CA2413338A1 Protein mixtures for wound healing |
| 01/03/2002 | CA2413301A1 Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| 01/03/2002 | CA2412635A1 Novel proteases |
| 01/03/2002 | CA2412610A1 Gp286 nucleic acids and polypeptides |
| 01/03/2002 | CA2412535A1 Polymorphic forms/hydrates of n-[4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)-quinazolin-6-yl]-acrylamide dihydrochloride |
| 01/03/2002 | CA2412084A1 Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest |
| 01/03/2002 | CA2411157A1 Benzodiazepines as inhibitors of hpv e1 helicase |
| 01/03/2002 | CA2381338A1 Human lyases |
| 01/03/2002 | CA2381241A1 Truncated egf receptor |
| 01/02/2002 | EP1167526A1 IgE-dependent histamine-releasing factor(HRF)receptor, HRF-binding peptides and nucleic acids encoding the same, and uses thereof |
| 01/02/2002 | EP1167379A2 Immunomodulatory oligonucleotides |
| 01/02/2002 | EP1167378A2 Immunomodulatory oligonucleotides |
| 01/02/2002 | EP1167377A2 Immunomodulatory oligonucleotides |
| 01/02/2002 | EP1167374A1 Glycosphingolipid |
| 01/02/2002 | EP1167363A2 Novel crystalline forms of (3S-trans)-2-(3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl)-4-(trifluoromethyl)-benzoic acid |
| 01/02/2002 | EP1166795A2 Skin cancer preventive agent containing sericin |
| 01/02/2002 | EP1166791A2 Antipsoriatic compositions comprising an asphodelus extract, method of making, and method of using |
| 01/02/2002 | EP1166789A2 Arsenolite containing angiogenesis inhibitor |
| 01/02/2002 | EP1166780A2 Use of physiologically acceptable sulfinic acid as antioxidant or radical scavenger in cosmetic or dermatologic preparations |
| 01/02/2002 | EP1166779A2 The use of nimesulide in the treatment of dermatological diseases |
| 01/02/2002 | EP1166771A1 Invers autoinversible latices based on fatty acid esters and cosmetic, dermocosmetic, dermopharmaceutic or pharmaceutic compositions |
| 01/02/2002 | EP1166769A1 Lipid composition containing a liquid crystal structure |
| 01/02/2002 | EP1166768A1 Use of ergothioneine and its derivatives as a glycation inhibitor |
| 01/02/2002 | EP1166765A2 Process for protecting human skin |
| 01/02/2002 | EP1165828A1 50 human secreted proteins |
| 01/02/2002 | EP1165827A1 45 human secreted proteins |
| 01/02/2002 | EP1165790A1 Protease activated receptor 2 variants |
| 01/02/2002 | EP1165789A2 Vesicle associated proteins |
| 01/02/2002 | EP1165788A2 Molecules of the immune system |
| 01/02/2002 | EP1165784A2 Nucleic acids including open reading frames encoding polypeptides; "orfx" |
| 01/02/2002 | EP1165781A2 Protease resistant flint analogs |
| 01/02/2002 | EP1165777A2 Genes encoding human potassium channel proteins |
| 01/02/2002 | EP1165615A2 MONOCLONAL ANTIBODIES AGAINST HUMAN PROTEIN Mcm3, PROCESS FOR THEIR PRODUCTION, AND THEIR USE |
| 01/02/2002 | EP1165614A1 Antibodies against phosphomannan that are protective against candidiasis |
| 01/02/2002 | EP1165606A1 50 human secreted proteins |
| 01/02/2002 | EP1165602A1 49 human secreted proteins |
| 01/02/2002 | EP1165590A1 49 human secreted proteins |
| 01/02/2002 | EP1165587A1 50 human secreted proteins |
| 01/02/2002 | EP1165575A1 Phosphate containing macrocyclic immunomodulators |
| 01/02/2002 | EP1165567A2 Sulfamate containing macrocyclic immunomodulators |
| 01/02/2002 | EP1165566A1 Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease |
| 01/02/2002 | EP1165562A1 Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 01/02/2002 | EP1165555A2 Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands |
| 01/02/2002 | EP1165545A1 Novel compounds |
| 01/02/2002 | EP1165544A1 Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase |
| 01/02/2002 | EP1165533A2 Compounds and methods for treatment of asthma, allergy and inflammatory disorders |
| 01/02/2002 | EP1165528A1 Novel morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives |
| 01/02/2002 | EP1165516A2 Heterocyclic urea and related compounds useful as anti-inflammatory agents |
| 01/02/2002 | EP1165514A1 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors |
| 01/02/2002 | EP1165513A1 Indolinone compounds as kinase inhibitors |
| 01/02/2002 | EP1165500A1 Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase |
| 01/02/2002 | EP1165495A1 Resorcinol derivatives |
| 01/02/2002 | EP1165491A1 Lta4 hydrolase inhibitors |
| 01/02/2002 | EP1165490A1 Substituted 2-aminobenzamide caspase inhibitors and the use thereof |
| 01/02/2002 | EP1165143A2 Method for expressing proteins |
| 01/02/2002 | EP1165115A1 Modulation of vascular permeability by mean of tie2 receptor activators |
| 01/02/2002 | EP1165114A1 Use of a lectin or conjugates for modulation of c-fibre activity |
| 01/02/2002 | EP1165099A2 Methods for limiting scar and adhesion formation |
| 01/02/2002 | EP1165085A1 Phthalazine derivatives for treating inflammatory diseases |
| 01/02/2002 | EP1165072A2 Valdecoxib compositions |
| 01/02/2002 | EP1165066A1 Use of lipoxin compounds for inhibiting of tnf-(alfa) initiated neutrophil response |
| 01/02/2002 | EP1165039A2 Dermatological topical composition |
| 01/02/2002 | EP1165035A2 Cosmetic or dermatological compositions containing at least one substance for increasing the functionality and/or expression of cd44 membrane receptors of skin cells |
| 01/02/2002 | EP1165033A1 Use of vitamin c or the like for stimulating skin cell synthesis |
| 01/02/2002 | EP1165032A1 Cosmetic and/or pharmaceutical preparations |
| 01/02/2002 | EP1165031A1 Resorcinol composition |
| 01/02/2002 | EP1165017A1 Liquid dispersion polymer compositions, their preparation and their use |
| 01/02/2002 | EP1164991A1 Gels formed by the interaction of poly(aldehyde) with various substances |
| 01/02/2002 | EP1135151A4 Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors |
| 01/02/2002 | EP1112053A4 Organosilicone compositions for personal care |
| 01/02/2002 | EP1051157B1 Controlled release delivery of peptide or protein |
| 01/02/2002 | EP0854703B1 Composition for treating keratinous material, including at least one silicone-grafted polymer and at least one thickening polymer or copolymer of (meth)acrylamide or a (meth)acrylamide derivative, and uses thereof |
| 01/02/2002 | EP0785938B1 Fused pyrrolocarbazoles |
| 01/02/2002 | EP0745074B1 4-amino derivatives of mycophenolic acid with immunosuppressant activity |
| 01/02/2002 | EP0600079B1 Oral 1alpha-hydroxyprevitamin d |
| 01/02/2002 | CN1329601A New benzimidazolone-benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |